

Aurora Kinase A - Pipeline Review, H2 2019

<https://marketpublishers.com/r/AB0624444DCCEN.html>

Date: December 2019

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: AB0624444DCCEN

Abstracts

Aurora Kinase A - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2019'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.

The report 'Aurora Kinase A - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action

(MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 2 and 2 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology which include indications Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Neuroblastoma, Ovarian Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, B-Cell Chronic Lymphocytic Leukemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Neuroendocrine Tumors, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer and Soft Tissue Sarcoma.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

The report reviews Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Overview

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Companies Involved in Therapeutics

Development

AbbVie Inc

Amgen Inc

Apollo Therapeutics LLC

CASI Pharmaceuticals Inc

Cielo Therapeutics Inc

Eli Lilly and Co

Merck & Co Inc

Millennium Pharmaceuticals Inc

Nanjing Tianyi Bioscience Co Ltd

Nanjing Transthera Biosciences Co Ltd

Taiho Pharmaceutical Co Ltd

Vichem Chemie Research Ltd

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related

Kinase 1 or AURKA or EC 2.7.11.1) - Drug Profiles

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APIOEE-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-137690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

danusertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBPR-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENMD-2076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3295668 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AURKA and AURKB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Aurora Kinase A for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TT-00420 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TY-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Dormant Products

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Discontinued Products

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related

Kinase 1 or AURKA or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Designation from FDA to treat Cholangiocarcinoma

Oct 02, 2018: Finding new combination therapies for Neuroblastoma

Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC

Jun 25, 2018: Combination Therapy May Revive Prospects for Embattled Breast Cancer Drugs

Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan

Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)

Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076

May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma

May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer

Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma

Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma

May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)

Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by CASI Pharmaceuticals Inc, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Dormant Products, H2 2019 (Contd..6), H2 2019
Dormant Products, H2 2019 (Contd..7), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Apollo Therapeutics LLC

CASI Pharmaceuticals Inc

Cielo Therapeutics Inc

Eli Lilly and Co

Merck & Co Inc

Millennium Pharmaceuticals Inc

Nanjing Tianyi Bioscience Co Ltd

Nanjing Transthera Biosciences Co Ltd

Taiho Pharmaceutical Co Ltd

Vichem Chemie Research Ltd

I would like to order

Product name: Aurora Kinase A - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/AB0624444DCCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB0624444DCCEN.html>